U.S. markets closed

AtriCure, Inc. (ATRC)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
30.42+0.28 (+0.93%)
Al cierre: 04:00PM EDT
30.42 0.00 (0.00%)
Fuera de horario: 04:02PM EDT

AtriCure, Inc.

7555 Innovation Way
Mason, OH 45040
United States
513 755 4100
https://www.atricure.com

Sector(es)Healthcare
IndustriaMedical Instruments & Supplies
Empleados a tiempo completo1,200

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Michael H. CarrelCEO, President & Director1.62MN/D1971
Ms. Angela L. Wirick CPAChief Financial Officer668.62kN/D1978
Mr. Douglas J. SeithChief Operating Officer989.17kN/D1966
Mr. Justin J. NozneskyChief Marketing & Strategy Officer644.73kN/D1978
Ms. Deborah YountChief Human Resources Officer498.36kN/D1966
Mr. Salvatore Privitera J.D.Chief Technical Officer471.15kN/D1967
Dr. Vinayak Doraiswamy Ph.D.Chief Scientific Officer777.66kN/D1972
Mr. Karl S. Dahlquist CCEP, J.D.Chief Legal OfficerN/DN/D1970
Valerie Storch-WillhausVice President of Corporate Marketing & CommunicationsN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Gestión corporativa

La calificación ISS Governance QuickScore de AtriCure, Inc. a partir del 1 de marzo de 2024 es 2. Las puntuaciones principales son Auditoría: 5; Junta: 1; Derechos del accionista: 3; Compensación: 3.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.